Logos Global Management LP Immatics N.V. Transaction History

Logos Global Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$10.23 - $12.94 $10.2 Million - $12.9 Million	1,000,000 New	1,000,000 $10.5 Million
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $6.06 Million - $6.94 Million	550,000 Added 110.0%	1,050,000 $12.2 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $2.96 Million - $6.36 Million	500,000 New	500,000 $5.77 Million

92.5M

313K

377K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $351M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.